Elevated ratio of C-type lectin-like receptor 2 level and platelet count (C2PAC) aids in the diagnosis of post-operative venous thromboembolism in IDH-wildtype gliomas
- PMID: 36706720
- DOI: 10.1016/j.thromres.2023.01.018
Elevated ratio of C-type lectin-like receptor 2 level and platelet count (C2PAC) aids in the diagnosis of post-operative venous thromboembolism in IDH-wildtype gliomas
Abstract
Introduction: Podoplanin (PDPN) is known to induce platelet aggregation via interacting with the C-type lectin-like receptor-2 on platelets and is involved in postoperative venous thromboembolism (VTE) formation. In this study, we investigate the correlation between soluble C-type lectin-like receptor (sCLEC-2) levels and PDPN expression in patients with high grade gliomas and the relationship between sCLEC-2 levels and the occurrence of VTE.
Materials and methods: Forty-four patients harboring high grade gliomas, treated surgically at the Department of Neurosurgery, Niigata University from April 2018 to August 2020, were included. Patients with high grade gliomas were divided into isocitrate dehydrogenase (IDH)- wildtype and mutant groups, and the presence or absence of VTE and the intensity of PDPN by immunohistochemistry were confirmed. Platelet counts, as well as plasma sCLEC-2 and PDPN were measured in these patients. Furthermore, the levels of sCLEC-2 concentration were divided by the platelet count (C2PAC index) for comparison.
Results: IDH-wildtype glioma patients highly expressed PDPN (P < 0.001) compared to IDH-mutant glioma patients. In total, 9 (20.5 %) patients were diagnosed with VTE during the follow-up period, of which 8 patients harbored IDH-wildtype gliomas, and one patient an IDH-mutant glioma. Mean sCLEC-2 levels and C2PAC index in patients with IDH-wildtype gliomas were significantly higher than that of low or no PDPN expression group, which included patients with IDH-mutant gliomas (P = 0.0004, P = 0.0002). In patients with IDH-wildtype gliomas, the C2PAC index in patients with VTE was significantly higher than in patients without VTE (P = 0.0492). The optimal cutoff point of C2PAC for predicting VTE in IDH-wildtype glioma patients was 3.7 with a sensitivity of 87.5 % and specificity of 51.9 %.
Conclusion: Platelet activation is strongly involved in the development of VTE in patients with IDH-wildtype high grade gliomas, and C2PAC index is a potential marker to detect VTE formation after surgery.
Keywords: CLEC-2; D-dimer; Isocitrate dehydrogenase; Malignant glioma; Podoplanin; Venous thromboembolism.
Copyright © 2023 Elsevier Ltd. All rights reserved.
Conflict of interest statement
Declaration of competing interest Masahide Kawamura and Kamon Shirakawa are employees of LSI Medience, but were not involved in data analysis. The authors have no other conflicts of interest to declare.
Similar articles
-
Podoplanin Expression and IDH-Wildtype Status Predict Venous Thromboembolism in Patients with High-Grade Gliomas in the Early Postoperative Period.World Neurosurg. 2019 Aug;128:e982-e988. doi: 10.1016/j.wneu.2019.05.049. Epub 2019 May 15. World Neurosurg. 2019. PMID: 31100523
-
Early recognition of sepsis-induced coagulopathy using the C2PAC index: a ratio of soluble type C lectin-like receptor 2 (sCLEC-2) level and platelet count.Platelets. 2022 Aug 18;33(6):935-944. doi: 10.1080/09537104.2021.2019694. Epub 2022 Jan 24. Platelets. 2022. PMID: 35073814
-
Isocitrate dehydrogenase mutation and risk of venous thromboembolism in glioma: A systematic review and meta-analysis.Thromb Res. 2022 Nov;219:14-21. doi: 10.1016/j.thromres.2022.08.029. Epub 2022 Sep 6. Thromb Res. 2022. PMID: 36088710
-
Risk of Venous Thromboembolism in Grade II-IV Gliomas as a Function of Molecular Subtype.Neurology. 2021 Feb 16;96(7):e1063-e1069. doi: 10.1212/WNL.0000000000011414. Epub 2020 Dec 22. Neurology. 2021. PMID: 33361259 Free PMC article.
-
Integrated diagnostics of diffuse astrocytic and oligodendroglial tumors.Pathologe. 2019 Jun;40(Suppl 1):9-17. doi: 10.1007/s00292-019-0581-8. Pathologe. 2019. PMID: 31025086 Review. English.
Cited by
-
Reply to Ishikura, H. What Does Soluble C-Type Lectin-like Receptor 2 (sCLEC-2) × D-Dimer/Platelet (PLT) (sCLEC-2 × D-Dimer/PLT) Mean for Coagulation/Fibrinolysis Conditions? Comment on "Yamamoto et al. Super Formula for Diagnosing Disseminated Intravascular Coagulation Using Soluble C-Type Lectin-like Receptor 2. Diagnostics 2023, 13, 2299".Diagnostics (Basel). 2023 Dec 25;14(1):42. doi: 10.3390/diagnostics14010042. Diagnostics (Basel). 2023. PMID: 38201352 Free PMC article.
-
Super Formula for Diagnosing Disseminated Intravascular Coagulation Using Soluble C-Type Lectin-like Receptor 2.Diagnostics (Basel). 2023 Jul 6;13(13):2299. doi: 10.3390/diagnostics13132299. Diagnostics (Basel). 2023. PMID: 37443690 Free PMC article.
-
Soluble C-type lectin-like receptor 2 in stroke (CLECSTRO) study: protocol of a multicentre, prospective cohort of a novel platelet activation marker in acute ischaemic stroke and transient ischaemic attack.BMJ Open. 2023 Sep 18;13(9):e073708. doi: 10.1136/bmjopen-2023-073708. BMJ Open. 2023. PMID: 37723115 Free PMC article.
-
What Does Soluble C-Type Lectin-like Receptor 2 (sCLEC-2) × D-Dimer/Platelet (PLT) (sCLEC-2 × D-Dimer/PLT) Mean for Coagulation/Fibrinolysis Conditions? Comment on Yamamoto et al. Super Formula for Diagnosing Disseminated Intravascular Coagulation Using Soluble C-Type Lectin-like Receptor 2. Diagnostics 2023, 13, 2299.Diagnostics (Basel). 2023 Dec 25;14(1):41. doi: 10.3390/diagnostics14010041. Diagnostics (Basel). 2023. PMID: 38201351 Free PMC article.
-
C-Type Lectin-like Receptor 2 Expression Is Decreased upon Platelet Activation and Is Lower in Most Tumor Entities Compared to Healthy Controls.Cancers (Basel). 2023 Nov 22;15(23):5514. doi: 10.3390/cancers15235514. Cancers (Basel). 2023. PMID: 38067218 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous